Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Buy” by Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been assigned an average rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $21.00.

A number of brokerages have recently commented on ZVRA. JMP Securities assumed coverage on shares of Zevra Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $17.00 price objective for the company. Maxim Group raised their target price on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Roth Mkm raised their price objective on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Canaccord Genuity Group decreased their target price on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday, September 18th.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA opened at $8.27 on Wednesday. Zevra Therapeutics has a fifty-two week low of $3.89 and a fifty-two week high of $8.95. The stock has a market capitalization of $346.12 million, a price-to-earnings ratio of -6.13 and a beta of 1.94. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. The business has a 50-day moving average of $7.10 and a 200-day moving average of $5.73.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The company had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. During the same quarter in the prior year, the company earned ($0.15) EPS. As a group, sell-side analysts predict that Zevra Therapeutics will post -1.58 earnings per share for the current fiscal year.

Insider Transactions at Zevra Therapeutics

In other news, Director Thomas Anderson bought 10,000 shares of the stock in a transaction dated Tuesday, July 16th. The shares were bought at an average price of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the purchase, the director now owns 20,000 shares in the company, valued at $136,200. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought a total of 22,000 shares of company stock worth $140,340 over the last quarter. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Armistice Capital LLC bought a new stake in shares of Zevra Therapeutics in the fourth quarter valued at about $1,755,000. Sanctuary Advisors LLC bought a new stake in Zevra Therapeutics in the 2nd quarter valued at about $474,000. Vanguard Group Inc. grew its position in shares of Zevra Therapeutics by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after purchasing an additional 58,866 shares in the last quarter. Retirement Planning Co of New England Inc. increased its holdings in shares of Zevra Therapeutics by 11.0% during the first quarter. Retirement Planning Co of New England Inc. now owns 430,193 shares of the company’s stock worth $2,495,000 after purchasing an additional 42,766 shares during the period. Finally, Mystic Asset Management Inc. raised its position in shares of Zevra Therapeutics by 15.4% in the first quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock valued at $1,545,000 after buying an additional 35,514 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.